Chronic opioid use in fibromyalgia syndrome: A clinical review

Journal of Clinical Rheumatology

Volumn 19, Issue 2, 2013, Pages 72-77

  Painter, Jacob T ^a   Crofford, Leslie J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

chronic nonmalignant pain; fibromyalgia (FM); opioid

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CLONAZEPAM; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; HYDROCODONE; IBUPROFEN; MILNACIPRAN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE RECEPTOR; OXYCODONE; PARACETAMOL; PAROXETINE; PLACEBO; PREGABALIN; TRAMADOL; ZOLPIDEM;

ANALGESIA; ANALGESIC ACTIVITY; CHRONIC DRUG ADMINISTRATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; FIBROMYALGIA; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANALGESICS, OPIOID; CHRONIC PAIN; FIBROMYALGIA; HUMANS;

EID: 84874948165     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3182863447     Document Type: Review

References (58)

1. Committee on Advancing Pain Research Care and Education. Relieving Pain in America. Washington, DC: Institute of Medicine; 2011
2. Buskila D. Developments in the scientific and clinical understanding of fibromyalgia. Arthritis Res Ther. 2009;11:242
3. Roskell NS, Beard SM, Zhao Y, et al. A meta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011;11:516-527
4. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28
5. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep. 2005;9:301-306
6. Le Merrer J, Becker JA, Befort K, et al. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89:1379-1412
7. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479-496
8. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953
9. Ueda H, Ueda M. Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci. 2009;14:5260-5272
10. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11:S5YS62
11. O'Callaghan JP, Miller DB. Spinal glia and chronic pain. Metabolism 2010;(59 suppl 1): S21YS26
12. Watkins LR, Hutchinson MR, Johnston IN, et al. Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci. 2005;28: 661-669
13. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63:772-810
14. Smythe HA, Moldofsky H. Two contributions to understanding of the ''fibrositis'' syndrome. Bull Rheum Dis. 1977;28:928-931
15. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944-952
16. Smith SB, Maixner DW, Fillingim RB, et al. Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum. 2012;64:584-593
17. Clauw DJ. Fibromyalgia: An overview. Am J Med. 2009;122:S3YS13
18. Williams DA, Clauw DJ. Understanding fibromyalgia: Lessons from the broader pain research community. J Pain. 2009;10:777-791
19. Petzke F, Harris RE, Williams DA, et al. Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. Eur J Pain. 2005;9:325-335
20. Gibson SJ, Littlejohn GO, Gorman MM, et al. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994;58:185-193
21. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343
22. Masuko K, Nakamura H. Functional somatic syndrome: How it could be relevant to rheumatologists. Mod Rheumatol. 2007;17:179-184
23. Bradley LA. Psychiatric comorbidity in fibromyalgia. Curr Pain Headache Rep. 2005;9:79-86
24. Kato K, Sullivan PF, Evengard B, et al. Chronic widespread pain and its comorbidities: A population-based study. Arch Intern Med. 2006;166: 1649-1654
25. Croft P, Rigby AS, Boswell R, et al. The prevalence of chronic widespread pain in the general population. J Rheumatol. 1993;20:710-713
26. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395
27. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7:362-368
28. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: Comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol. 1999;26:1577-1585
29. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48:2916-2922
30. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken ;62:600-610
31. Hauser W, Eich W, Herrmann M, et al. Fibromyalgia syndrome: Classification, diagnosis, and treatment. Dtsch Arztebl Int. 2009;106: 383-391
32. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541
33. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005
34. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalinVa meta-analysis of randomized controlled trials. Pain. 2009;145:69-81
35. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51:9-13
36. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236
37. Crofford LJ, RowbothamMC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-1273
38. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15
39. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409
40. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009;301:198-209
41. Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: A controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18:13-19
42. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537-545
43. Rosenthal N. Important Drug Warning. 2010 [cited August 24, 2011]. Available at: Http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ UCM213265.pdf; Accessed August 15, 2011
44. Zhao Y, Sun P,Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11:204-216
45. Backonja MM, Irving G, Argoff C. Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep. 2006;10:34-38
46. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11:505-521
47. Bennett RM, Jones J, Turk DC, et al. An Internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27
48. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10: 113-130
49. Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality. The DAWN report: Highlights of the 2009 Drug Abuse Warning Network (DAWN) finding on drug-related emergency department visits. December 28, 2010 [cited August 11, 2011]. Available at: Http:www.oas.samhsa.gov/2-10/ DAWN034/EDHighlights.cfm; Accessed August 15, 2011
50. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105YS120
51. Manchikanti L, Vallejo R, Manchikanti KN, et al. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician. 2011;14:E133YE156
52. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009;6:703-712
53. Harris RE, ClauwDJ, Scott DJ, et al. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:10000-10006
54. Baraniuk JN, Whalen G, Cunningham J, et al. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48
55. Becker H, Stuifbergen A, Taxis C, et al. The use of goal attainment scaling to facilitate and assess individualized change in a wellness intervention for women with fibromyalgia syndrome. J Holist Nurs. 2009;27:232-240
56. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am. 2002;28:261-290
57. Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis. 2011;14:6-11
58. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev. 2007;11:35-46